Literature DB >> 7505799

Tolerogenicity of resting and activated B cells.

K M Gilbert1, W O Weigle.   

Abstract

Antigen presentation by resting splenic B cells has been shown previously to induce T helper 1 cell (Th1) anergy. In contrast to expectations, it was found here that B cells treated with F(ab')2 goat anti-mouse immunoglobulin (IgM) for 24 or 48 h also presented antigen (Ag) to Th1 cells in a manner that induced dramatic Ag-specific proliferative inactivation. The tolerogenicity of the anti-Ig-treated B cells was consistent with the observation that these B cells were only slightly more efficient than resting B cells in stimulating human gamma globulin (HGG)-induced proliferation of HGG-specific Th1 cells in primary cultures. The activated B cells were, however, more efficient than resting B cells in stimulating a primary mixed leukocyte reaction, and exhibited increased expression of major histocompatibility complex class II molecules, RL388 Ag and transferrin receptor. In addition, unlike resting B cells, which expressed little detectable B7, anti-Ig-treated B cells expressed high levels of B7. The functional capacity of the B7 expressed on the activated B cells was demonstrated by the fact that the Ag-presenting capacity of these B cells was inhibited by the addition to culture of CTLA4Ig, a soluble receptor for B7. It is unlikely that the tolerogenicity of the activated B cells was due to an inability of the Th1 cells to respond to B7 signals; the Th1 clones used in the experiments, unlike the Th2 clones tested, expressed CD28, the ligand for B7. In addition, anti-CD28 monoclonal antibody inhibited the induction of Th1 cell anergy when added to cultures of Th1 cells and Ag-pulsed fixed antigen-presenting cells. Taken together, the results indicate that B cells, even when activated, do not satisfy the costimulatory requirements of the Th1 cells used here, and therefore can present Ag in a tolerogenic fashion to Th1 cells. The costimulator deficiency of activated B cells may reflect an inadequacy in the level of B7 expressed or a lack of some other molecule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7505799      PMCID: PMC2191345          DOI: 10.1084/jem.179.1.249

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  49 in total

1.  Activation and proliferation signals in mouse B cells. VI. Anti-Ig antibodies induce dose-dependent cell cycle progression in B cells.

Authors:  G G Klaus; C M Hawrylowicz; C J Carter
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

2.  BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus.

Authors:  D A Thorley-Lawson; L M Nadler; A K Bhan; R T Schooley
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

3.  Anti-immunoglobulin augments the B-cell antigen-presentation function independently of internalization of receptor-antigen complex.

Authors:  L A Casten; E K Lakey; M L Jelachich; E Margoliash; S K Pierce
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Characterization of antigen processing and presentation by resting B lymphocytes.

Authors:  E J Gosselin; H P Tony; D C Parker
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

5.  Different antigen-presenting cells differ in their capacity to induce lymphokine production and proliferation of an apo-cytochrome c-specific T cell clone.

Authors:  S Baumhüter; C Bron; G Corradin
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

6.  B cells as antigen-presenting cells: the requirement for B cell activation.

Authors:  T Kakiuchi; R W Chesnut; H M Grey
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

7.  Level of mIa expression on mitogen-stimulated murine B lymphocytes is dependent on position in cell cycle.

Authors:  J G Monroe; J C Cambier
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

8.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.

Authors:  T Yokochi; R D Holly; E A Clark
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  Expression of membrane activation antigens on murine B lymphocytes stimulated with lipopolysaccharide.

Authors:  D N Ernst; D N McQuitty; W O Weigle; M V Hobbs
Journal:  Cell Immunol       Date:  1988-06       Impact factor: 4.868

10.  Induction and mode of action of suppressor cells generated against human gamma globulin. I. An immunologic unresponsive state devoid of demonstrable suppressor cells.

Authors:  D E Parks; M V Doyle; W O Weigle
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

View more
  26 in total

1.  Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness.

Authors:  Y Kang; M Melo; E Deng; R Tisch; M El-Amine; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance.

Authors:  Melanie P Matheu; Yan Su; Milton L Greenberg; Caroline A Blanc; Ian Parker; David W Scott; Michael D Cahalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-17       Impact factor: 11.205

Review 3.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 4.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

Review 5.  Immunologic tolerance in renal transplantation.

Authors:  D A Shoskes
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes.

Authors:  E T Zambidis; A Kurup; D W Scott
Journal:  Mol Med       Date:  1997-03       Impact factor: 6.354

7.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Authors:  R K Agarwal; Y Kang; E Zambidis; D W Scott; C C Chan; R R Caspi
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

8.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

Authors:  Tie Chi Lei; David W Scott
Journal:  Blood       Date:  2005-03-15       Impact factor: 22.113

Review 9.  CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.

Authors:  E Kondo; L Gryschok; N Klein-Gonzalez; S Rademacher; M R Weihrauch; T Liebig; A Shimabukuro-Vornhagen; M Kochanek; A Draube; M S von Bergwelt-Baildon
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

10.  B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway.

Authors:  Yan Su; Gregory Carey; Maja Maric; David W Scott
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.